Spermosens Q2 operating loss widens to SEK 2.78 million

• Spermosens reported a Q2 operating loss of SEK 2.78 million, widening from SEK 2.66 million a year earlier.
• Cash and cash equivalents fell to SEK 1.88 million at June 30 from SEK 12.86 million a year earlier.
• Equity declined to SEK 27.45 million from SEK 36.88 million; earnings per share improved to SEK -0.001 from SEK -0.02.
• Recruitment in the Generation 3 JUNO-Checked clinical validation study exceeded expectations, reaching 44 patients before the summer break.
• Management said it secured a SEK 4.85 million capital facility to extend runway and support completion of the study by year-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spermosens AB published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.